Do GLP-1 Drugs Reduce Asthma Risk? Meta-Analysis of 85,755 Patients
A meta-analysis of 39 trials and 85,755 patients found a modest but non-significant trend toward reduced asthma incidence with GLP-1 drugs, with light-molecular-weight GLP-1 agonists showing a significant 35% reduction.
Quick Facts
What This Study Found
GLP-1 receptor-based agonists showed a non-significant 9% asthma risk reduction overall (RR 0.91, 95% CI 0.68-1.24), but light-molecular-weight GLP-1RAs showed a significant 35% reduction (RR 0.65, 95% CI 0.43-0.99, P=0.043).
Key Numbers
Meta-analysis pooling data from multiple studies across databases examining GLP-1 RA use and asthma outcomes.
How They Did This
Systematic review and meta-analysis of 39 RCTs (85,755 participants) from PubMed, Web of Science, Embase, Cochrane CENTRAL, and ClinicalTrials.gov through July 2023. Used fixed-effects model with subgroup analyses by drug structure, duration, and molecular weight.
Why This Research Matters
If GLP-1 drugs can reduce asthma risk in the millions of people taking them for diabetes and obesity, it would be a significant secondary benefit — especially since these conditions frequently overlap and obesity worsens asthma.
The Bigger Picture
The anti-inflammatory properties of GLP-1 drugs extend beyond metabolic effects. This meta-analysis provides initial evidence that these peptide drugs may influence airway inflammation, though the overall signal is weak. As GLP-1 drugs are prescribed to more people for longer durations, clearer patterns may emerge — particularly for specific drug subtypes.
What This Study Doesn't Tell Us
Overall result was not statistically significant. Asthma was typically an incidental finding in diabetes/obesity trials, not a primary endpoint. Weight loss itself could reduce asthma risk. The significant finding for light-molecular-weight GLP-1RAs may reflect subgroup multiplicity. Different GLP-1 drugs and doses were pooled.
Questions This Raises
- ?Would a dedicated trial of GLP-1 drugs in asthma patients confirm the potential benefit?
- ?Why might light-molecular-weight GLP-1 agonists show a stronger effect than larger molecules?
- ?Is the potential asthma benefit driven by weight loss, anti-inflammatory effects, or direct airway GLP-1 receptor activation?
Trust & Context
- Key Stat:
- 35% asthma reduction with light-molecular-weight GLP-1 agonists, though the overall GLP-1 class showed only a non-significant 9% trend
- Evidence Grade:
- Moderate evidence: large meta-analysis with nearly 86,000 participants, but the primary finding was not statistically significant and asthma was a secondary outcome in most included trials.
- Study Age:
- Published in 2024 with data through July 2023. First major meta-analysis examining GLP-1 drugs and asthma risk.
- Original Title:
- The Association between GLP-1 Receptor-Based Agonists and the Incidence of Asthma in Patients with Type 2 Diabetes and/or Obesity: A Meta-Analysis.
- Published In:
- Biomedical and environmental sciences : BES, 37(6), 607-616 (2024)
- Authors:
- Zhang, Meng Qing, Lin, Chu(4), Cai, Xiao Ling, Jiao, Ruo Yang, Bai, Shu Zhen, Li, Zong Lin, Hu, Sui Yuan, Lyu, Fang, Yang, Wen Jia, Ji, Li Nong
- Database ID:
- RPEP-09646
Evidence Hierarchy
Combines results from multiple studies to find an overall pattern.
What do these levels mean? →Frequently Asked Questions
Can GLP-1 drugs help with asthma?
This large meta-analysis found a modest trend toward reduced asthma risk with GLP-1 drugs, but the overall result was not statistically significant. One subtype (light-molecular-weight GLP-1 agonists) showed a significant 35% reduction. More research is needed before GLP-1 drugs can be recommended for asthma.
Why might GLP-1 drugs affect asthma?
GLP-1 receptors are found in lung tissue, and GLP-1 drugs have anti-inflammatory properties that could reduce airway inflammation. Additionally, weight loss from GLP-1 drugs may independently improve asthma, since obesity is a major asthma risk factor.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09646APA
Zhang, Meng Qing; Lin, Chu; Cai, Xiao Ling; Jiao, Ruo Yang; Bai, Shu Zhen; Li, Zong Lin; Hu, Sui Yuan; Lyu, Fang; Yang, Wen Jia; Ji, Li Nong. (2024). The Association between GLP-1 Receptor-Based Agonists and the Incidence of Asthma in Patients with Type 2 Diabetes and/or Obesity: A Meta-Analysis.. Biomedical and environmental sciences : BES, 37(6), 607-616. https://doi.org/10.3967/bes2024.067
MLA
Zhang, Meng Qing, et al. "The Association between GLP-1 Receptor-Based Agonists and the Incidence of Asthma in Patients with Type 2 Diabetes and/or Obesity: A Meta-Analysis.." Biomedical and environmental sciences : BES, 2024. https://doi.org/10.3967/bes2024.067
RethinkPeptides
RethinkPeptides Research Database. "The Association between GLP-1 Receptor-Based Agonists and th..." RPEP-09646. Retrieved from https://rethinkpeptides.com/research/zhang-2024-the-association-between-glp1
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.